|
1
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Surveillance E; End Results (SEER)
Program: (www.seer.cancer.gov) SEER*Stat
Database: Mortality - All COD, Aggregated With State, Total U.S.
(1969–2010) <Katrina/Rita Population Adjustment>, National
Cancer Institute, DCCPS, Surveillance Research Program,
Surveillance Systems Branch, released April 2013. Underlying
mortality data provided by NCHS (www.cdc.gov/nchs)
|
|
4
|
Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu
L and He J: The incidences and mortalities of major cancers in
China, 2009. Chin J Cancer. 32:106–112. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Smith RA, Cokkinides V and Eyre HJ: Cancer
screening in the United States, 2007: A review of current
guidelines, practices, and prospects. CA Cancer J Clin. 57:90–104.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Slawin KM, Ohori M, Dillioglugil O and
Scardino PT: Screening for prostate cancer: An analysis of the
early experience. CA Cancer J Clin. 45:134–147. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Catalona WJ, Richie JP, Ahmann FR, Hudson
MA, Scardino PT, Flanigan RC, deKernion JB, Ratliff TL, Kavoussi
LR, Dalkin BL, et al: Comparison of digital rectal examination and
serum prostate specific antigen in the early detection of prostate
cancer: Results of a multicenter clinical trial of 6,630 men. J
Urol. 151:1283–1290. 1994.PubMed/NCBI
|
|
8
|
Cher ML and Carroll PR: Screening for
prostate cancer. West J Med. 162:235–242. 1995.PubMed/NCBI
|
|
9
|
Schmidt JD: Clinical diagnosis of prostate
cancer. Cancer. 70(Suppl 1): 221–224. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lilja H: Biology of prostate-specific
antigen. Urology. 62(Suppl 1): 27–33. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yates DR and Catto JW: Distinct patterns
and behaviour of urothelial carcinoma with respect to anatomical
location: How molecular biomarkers can augment clinicopathological
predictors in upper urinary tract tumours. World J Urol. 31:21–29.
2013. View Article : Google Scholar
|
|
12
|
Clarke RA, Zhao Z, Guo AY, Roper K, Teng
L, Fang ZM, Samaratunga H, Lavin MF and Gardiner RA: New genomic
structure for prostate cancer specific gene PCA3 within BMCC1:
Implications for prostate cancer detection and progression. PLoS
One. 4:e49952009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roddam AW, Duffy MJ, Hamdy FC, Ward AM,
Patnick J, Price CP, Rimmer J, Sturgeon C, White P and Allen NE;
NHS Prostate Cancer Risk Management: Use of prostate-specific
antigen (PSA) isoforms for the detection of prostate cancer in men
with a PSA level of 2–10 ng/ml: Systematic review and
meta-analysis. Eur Urol. 48:386–399. 2005. View Article : Google Scholar
|
|
14
|
Bussemakers MJ, van Bokhoven A, Verhaegh
GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N and Isaacs
WB: DD3: A new prostate-specific gene, highly overexpressed in
prostate cancer. Cancer Res. 59:5975–5979. 1999.PubMed/NCBI
|
|
15
|
Hessels D, Klein Gunnewiek JM, van Oort I,
Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA
and Schalken JA: DD3(PCA3)-based molecular urine analysis for the
diagnosis of prostate cancer. Eur Urol. 44:8–16. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schalken JA, Hessels D and Verhaegh G: New
targets for therapy in prostate cancer: Differential display code 3
(DD3(PCA3)), a highly prostate cancer-specific gene. Urology.
62(Suppl 1): 34–43. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
de Kok JB, Verhaegh GW, Roelofs RW,
Hessels D, Kiemeney LA, Aalders TW, Swinkels DW and Schalken JA:
DD3(PCA3), a very sensitive and specific marker to detect prostate
tumors. Cancer Res. 62:2695–2698. 2002.PubMed/NCBI
|
|
18
|
Day JR, Jost M, Reynolds MA, Groskopf J
and Rittenhouse H: PCA3: From basic molecular science to the
clinical lab. Cancer Lett. 301:1–6. 2011. View Article : Google Scholar
|
|
19
|
Ploussard G and de la Taille A: Urine
biomarkers in prostate cancer. Nat Rev Urol. 7:101–109. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roobol MJ: Contemporary role of prostate
cancer gene 3 in the management of prostate cancer. Curr Opin Urol.
21:225–229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roobol MJ, Haese A and Bjartell A: Tumour
markers in prostate cancer III: Biomarkers in urine. Acta Oncol.
50(Suppl 1): 85–89. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Marks LS, Fradet Y, Deras IL, Blase A,
Mathis J, Aubin SM, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse
H, et al: PCA3 molecular urine assay for prostate cancer in men
undergoing repeat biopsy. Urology. 69:532–535. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Janegitz BC, Cancino J and Zucolotto V:
Disposable biosensors for clinical diagnosis. J Nanosci
Nanotechnol. 14:378–389. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McCarroll J, Teo J, Boyer C, Goldstein D,
Kavallaris M and Phillips PA: Potential applications of
nanotechnology for the diagnosis and treatment of pancreatic
cancer. Front Physiol. 5:22014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Thakor AS and Gambhir SS: Nanooncology:
The future of cancer diagnosis and therapy. CA Cancer J Clin.
63:395–418. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chan CP, Cheung YC, Renneberg R and
Seydack M: New trends in immunoassays. Adv Biochem Eng Biotechnol.
109:123–154. 2008.
|
|
27
|
Sandhu A, Handa H and Abe M: Synthesis and
applications of magnetic nanoparticles for biorecognition and point
of care medical diagnostics. Nanotechnology. 21:4420012010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Casadio V, Calistri D, Salvi S, Gunelli R,
Carretta E, Amadori D, Silvestrini R and Zoli W: Urine cell-free
DNA integrity as a marker for early prostate cancer diagnosis: A
pilot study. Biomed Res Int. 2013:2704572013. View Article : Google Scholar
|
|
29
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ahyai SA, Graefen M, Steuber T, Haese A,
Schlomm T, Walz J, Köllermann J, Briganti A, Zacharias M, Friedrich
MG, et al: Contemporary prostate cancer prevalence among T1c
biopsy-referred men with a prostate-specific antigen level ≤4.0 ng
per milliliter. Eur Urol. 53:750–757. 2008. View Article : Google Scholar
|
|
31
|
Thompson IM, Pauler DK, Goodman PJ, Tangen
CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford
ED, et al: Prevalence of prostate cancer among men with a
prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J
Med. 350:2239–2246. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Groskopf J, Aubin SM, Deras IL, Blase A,
Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, et al:
APTIMA PCA3 molecular urine test: development of a method to aid in
the diagnosis of prostate cancer. Clin Chem. 52:1089–1095. 2006.
View Article : Google Scholar : PubMed/NCBI
|
